# A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

> **NCT05007392** · PHASE3 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 451 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Dotinurad
- **DRUG:** Febuxostat
- **OTHER:** Dotinurad Matched Placebo
- **OTHER:** Febuxostat Matched Placebo

## Key facts

- **NCT ID:** NCT05007392
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-21
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007392, "A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05007392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*